Research Topics
Species | Andrew LeuchterSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Resting-state quantitative electroencephalography reveals increased neurophysiologic connectivity in depressionAndrew F Leuchter
Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, United States of America
PLoS ONE 7:e32508. 2012..These results can inform the development of qEEG state and trait biomarkers for MDD...- An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorderAndrew F Leuchter
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
J Psychiatr Pract 14:271-80. 2008..This pilot study was conducted to evaluate this combination in the treatment of MDD in patients with chronic or recurrent MDD to estimate safety, tolerability, and remission rates... 
Changes in brain function during administration of venlafaxine or placebo to normal subjectsAndrew F Leuchter
Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
Clin EEG Neurosci 39:175-81. 2008..Future studies should examine other classes of medication, as well as antidepressants with other mechanisms of action, to determine if cordance detects antidepressant medication effects in general in normal subjects...
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) reportA F Leuchter
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
Psychol Med 40:239-51. 2010..Whether PPS significantly contribute to poorer treatment outcome overall in primary or specialty psychiatric care settings remains unclear...- Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidenceAndrew F Leuchter
Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
Clin EEG Neurosci 40:78-83. 2009..The current state of evidence supporting the use of each technique is reviewed... - Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorderAndrew F Leuchter
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 760 Westwood Plaza, Rm 37 452, Los Angeles, CA 90024 1759, USA
J Clin Psychopharmacol 29:372-7. 2009..These findings support the hypothesis that genetic polymorphisms modulating monoaminergic tone are related to degree of placebo responsiveness in major depressive disorder... - Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorderAndrew F Leuchter
Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
Psychiatry Res 169:132-8. 2009..28%). The ATR index did not provide a useful prediction of response to combination treatment. The ATR index may prove useful in predicting responsiveness to different antidepressant medications... - Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD studyAndrew F Leuchter
Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
Psychiatry Res 169:124-31. 2009..Logistic regression showed that the ATR and early Ham-D(17) changes were additive predictors of response, but the ATR was the only significant predictor of remission. Future studies should replicate these results prior to clinical use... - A new paradigm for the prediction of antidepressant treatment responseAndrew F Leuchter
Laboratory of Brain Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024, USA
Dialogues Clin Neurosci 11:435-46. 2009..We posit that this new paradigm could lead to earlier recovery from depressive illness and ultimately produce profound health and economic benefits... - Biomarkers to predict antidepressant responseAndrew F Leuchter
Semel Institute for Neuroscience and Human Behavior at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA
Curr Psychiatry Rep 12:553-62. 2010..Once such biomarkers are validated, they could form the basis of new paradigms for antidepressant treatment selection... - Changes in brain function of depressed subjects during treatment with placeboAndrew F Leuchter
UCLA Neuropsychiatric Institute, Los Angeles, CA 90024 1759, USA
Am J Psychiatry 159:122-9. 2002..Both QEEG power and cordance, a new measure that reflects cerebral perfusion and is sensitive to the effect of antidepressant medication, were examined... - Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depressionAndrew F Leuchter
UCLA NPI, 760 Westwood Plaza, Suite 37 452, Los Angeles, CA 90024 1759, USA
Psychopharmacology (Berl) 177:15-22. 2004..High placebo response rates are a confound in treatment trials for major depressive disorder (MDD). A method for prospective identification of placebo responders could enhance the efficiency of clinical trials... - Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot studyAimee M Hunter
Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at the University of California, Los Angeles, CA, USA
Pain Med 10:730-8. 2009..We hypothesized that cordance might also predict response to antidepressant medications for symptoms of FMS... - Predictors of improved mood over time in clinical trials for major depressionAriane Marie-Mitchell
Department of Preventive Medicine, University of Southern California Keck School of Medicine, 1540 Alcazar St, CHP 218, Los Angeles, CA 90033 9010, USA
Psychiatry Res 127:73-84. 2004..We recommend the use of repeated measures modeling, and the exploration of relationships among biological and psychological factors, for future analyses of clinical trial data... - Influence of age, gender, health status, and depression on quantitative EEGMelinda L Morgan
Behavioral Pharmacology Laboratory, UCLA Neuropsychiatric Institute, USA
Neuropsychobiology 52:71-6. 2005..Global measures of power, and to a lesser extent prefrontal absolute power, must be interpreted with regard to confounding factors of age, gender, physical illness, and severity of depression... - Amygdala lateralization at rest and during viewing of neutral faces in major depressive disorder using low-resolution brain electromagnetic tomographyHaleh Farahbod
Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA 90024 1759, USA
Clin EEG Neurosci 41:19-23. 2010..Findings suggest a more pronounced lateralization effect in normal healthy controls than in MDD subjects when changing from a resting (eyes-closed) condition to viewing faces without emotional valence... - Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attritionSandy Venneman
Medication Development Unit, Research Service, and Psychiatry Service, West Los Angeles VA Medical Center, California, USA
J Neuropsychiatry Clin Neurosci 18:208-16. 2006..Failure to complete the trial was not explained by depression, craving, benzoylecgonine levels or quantitative electroencephalogram (QEEG) power; thus cordance may help identify attrition risk... - Longitudinal progression of subclinical structural brain disease in normal agingIan A Cook
UCLA Neuropsychiatric Institute and the Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA 90024 1759, USA
Am J Geriatr Psychiatry 12:190-200. 2004..Greater volumes were also associated with poorer cognition, even though subjects performed within the normal range. The natural history of these forms of SSBD and their functional impact are not well established... - Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depressionAlexander S Korb
Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
Clin Neurophysiol 120:1313-9. 2009.... - Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteersThomas F Newton
Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, UCLA School of Medicine, Room A7 372, 760 Westwood Plaza, Los Angeles, CA 90024, USA
Clin Neurophysiol 115:194-8. 2004..Exposure to methamphetamine is associated with long-lasting reductions in markers for dopaminergic neurons in preclinical models and in humans. These changes may be associated with alterations in brain electrical activity and in cognition... - Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorderAimee M Hunter
Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, United States
J Psychiatr Res 44:90-8. 2010..Statistical methods such as GMM are needed to identify clinically relevant symptom response trajectories... - Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individualsThomas F Newton
Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
Clin Neurophysiol 114:410-5. 2003.... - Cognitive and physiologic correlates of subclinical structural brain disease in elderly healthy control subjectsIan A Cook
University of California, Los Angeles, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024 1759, USA
Arch Neurol 59:1612-20. 2002..Healthy elderly persons commonly show 4 types of change in brain structure-cortical atrophy, central atrophy, deep white-matter hyperintensities, and periventricular hyperintensities-as forms of subclinical structural brain disease (SSBD)... - Midline and right frontal brain function as a physiologic biomarker of remission in major depressionIan A Cook
UCLA Depression Research and Clinic Program, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, United States
Psychiatry Res 174:152-7. 2009..These results suggest that remission may be predictable from physiologic measurements after 1 week of treatment, and that this region merits further investigation in the neurobiology of treatment response... - Estrogen replacement therapy is associated with less progression of subclinical structural brain disease in normal elderly women: a pilot studyIan A Cook
UCLA Neuropsychiatric Institute and the Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine Los Angeles, CA 90024 1759, USA
Int J Geriatr Psychiatry 17:610-8. 2002..Cortical atrophy, central atrophy, deep white-matter hyperintensities, and periventricular hyperintensities are reported in normal aging... - Early changes in prefrontal activity characterize clinical responders to antidepressantsIan A Cook
Quantitative EEG Laboratory, Neuropsychiatric Institute and Hospital, UCLA School of Medicine, University of California, 760 Westwood Plaza, Los Angeles, CA 90024 1759, USA
Neuropsychopharmacology 27:120-31. 2002..These findings implicate the prefrontal region in mediating response to antidepressant medications. Cordance may have clinical applicability as a leading indicator of individual response... - Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placeboAimee M Hunter
Behavioral Pharmacology Laboratory, Department of Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, David Geffen School of Medicine, Los Angeles, CA 90024 1759, USA
Neuropsychopharmacology 30:792-9. 2005..Results of these exploratory hypothesis-generating analyses should be considered tentative until replicated... - Brain electrical source differences between depressed subjects and healthy controlsAlexander S Korb
Laboratory of Brain, Behavior, and Pharmacology, Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
Brain Topogr 21:138-46. 2008..Inconsistent findings among LORETA studies, and between LORETA studies and those using other functional imaging techniques, may result from differences in electrode montages... - Estrogen augmentation of antidepressants in perimenopausal depression: a pilot studyMelinda L Morgan
Laboratory of Behavioral Pharmacology, University of California Los Angeles Neuropsychiatric Institute and Hospital, Department of Psychiatry and Biobehavioral Sciences, 90024, USA
J Clin Psychiatry 66:774-80. 2005..To investigate the effects of estrogen augmentation on mood and memory in women with perimenopausal depression who had experienced a partial response to antidepressant medications... - Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot studyIan A Cook
Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute, 760 Westwood Plaza, 37 451, Los Angeles, CA 90024 1759, USA
J Psychiatr Res 39:461-6. 2005..These findings suggest that cordance biomarkers may be a useful tool in effectiveness trials that parallel clinical practices in SSRI nonresponders, and may not require a wash-out period between treatments... - Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back painHeather V Krell
Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute, 37 452 NPI, 760 Westwood Plaza, Los Angeles, CA 90024, USA
Psychosomatics 46:379-84. 2005..Our experience with reboxetine suggests that this noradrenergic antidepressant may have efficacy in the treatment of chronic pain in patients with depression... - Neurophysiologic changes during estrogen augmentation in perimenopausal depressionMelinda L Morgan
Laboratory of Brain, Behavior, and Pharmacology, Department of Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, 760 Westwood Plaza, Suite 37 439, Los Angeles, CA 90024 1759, United States
Maturitas 56:54-60. 2007..We also assessed whether such changes were correlated with serum hormone levels... - Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressantHeather V Krell
Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
J Clin Psychiatry 65:1174-9. 2004..To evaluate the association between treatment expectations and response in a 9-week, single-blind experimental antidepressant treatment study... - Aging and brain activation with working memory tasks: an fMRI study of connectivityIan A Cook
UCLA Semel Institute for Neuroscience and Human Behavior, California 90024 1759, USA
Int J Geriatr Psychiatry 22:332-42. 2007..We hypothesized healthy older subjects would show lower connectivity than younger subjects... - The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorderAimee M Hunter
Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024 1759, USA
Psychiatr Clin North Am 30:105-24. 2007.... - Insured and non-insured depressed outpatients: how do they compare?Ira M Lesser
Department of Psychiatry, Harbor UCLA Medical Center, The Los Angeles Biomedical Research Institute, Los Angeles, CA, USA
Ann Clin Psychiatry 19:73-82. 2007.... - Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depressionAimee M Hunter
Semel Institute for Neuroscience and Human Behavior at UCLA, 760 Westwood Plaza, Rm 37 359, Los Angeles, CA 90024 1759, USA
Am J Psychiatry 163:1426-32. 2006..The authors hypothesized that decreases in prefrontal cordance during the placebo lead-in phase would be associated with better clinical outcome in subjects treated with antidepressants... - Pretreatment neurophysiologic function and ECT response in depressionWilliam F Stubbeman
Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA
J ECT 20:142-4. 2004..The location of central electrodes over the cingulate cortex may indicate that pretreatment cingulate activity is associated with response to ECT... - Does the clinical course of depression determine improvement in symptoms and quality of life?Tally Moses
School of Social Work, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
J Nerv Ment Dis 194:241-8. 2006..Our results support the trend of distinguishing between treatment-related change in QOL and symptomatic change and suggest clinical course factors as promising predictors of QOL... - Characteristics of insured and noninsured outpatients with depression in STAR(*)DIra M Lesser
Harbor UCLA Medical Center, Box 8, 1000 West Carson Street, Torrance, California 90509, USA
Psychiatr Serv 56:995-1004. 2005....
Research Grants
- ENHANCING TREATMENT OUTCOMES IN DEPRESSIONAndrew Leuchter; Fiscal Year: 2004In this competing renewal application for a K02 award, Dr. Andrew Leuchter proposes a line of research and career enhancement aimed at improving outcomes of treatment for depression...
- Psychobiologic Factors of the Placebo Response in MDDAndrew Leuchter; Fiscal Year: 2007..The results of this project will lead to better understanding of the mechanisms of the placebo response in MDD. ..
- RESEARCH TRAINING: PSYCHOBIOLOGICAL SCIENCESAndrew Leuchter; Fiscal Year: 2007..The University is providing financial support for this predoctoral training program. These changes should lead to an enhanced training experience for a more diverse group of postdoctoral and predoctoral trainees. ..